Proton Pump Inhibitors Increase Risk for Hepatic Encephalopathy in Patients With Cirrhosis in A Population Study

Gastroenterology

Volumn 152, Issue 1, 2017, Pages 134-141

  Tsai, Chia Fen ^a,b   Chen, Mu Hong ^a,b   Wang, Yen Po ^a,b   Chu, Chi Jen ^a,b   Huang, Yi Hsiang ^a,b   Lin, Han Chieh ^a,b   Hou, Ming Chih ^a,b   Lee, Fa Yauh ^a,b   Su, Tung Ping ^a,b   Lu, Ching Liang ^a,b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Acid Suppression; Cognitive Dysfunction; Gut Microbiota; Liver Failure

Indexed keywords

ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; 2 [[(2 PYRIDYL)METHYL]SULFINYL]BENZIMIDAZOLE DERIVATIVE;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DOSE RESPONSE; FEMALE; FOLLOW UP; HEPATIC ENCEPHALOPATHY; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MIDDLE AGED; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; TAIWAN; ADMINISTRATIVE CLAIMS (HEALTH CARE); AGED; CASE CONTROL STUDY; COMPLICATION; HEALTH INSURANCE; INCIDENCE; LONGITUDINAL STUDY; STATISTICS AND NUMERICAL DATA;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADMINISTRATIVE CLAIMS, HEALTHCARE; ADULT; AGED; CASE-CONTROL STUDIES; ESOMEPRAZOLE; FEMALE; HEPATIC ENCEPHALOPATHY; HUMANS; INCIDENCE; INSURANCE, HEALTH; LANSOPRAZOLE; LIVER CIRRHOSIS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; OMEPRAZOLE; PROTON PUMP INHIBITORS; RABEPRAZOLE; TAIWAN;

EID: 85006312492     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2016.09.007     Document Type: Article

References (54)

1. 1 Vilstrup, H., Amodio, P., Bajaj, J., et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology 60 (2014), 715–735.
2. 2 Prakash, R., Mullen, K.D., Mechanisms, diagnosis and management of hepatic encephalopathy. Nat Rev Gastroenterol Hepatol 7 (2010), 515–525.
3. 3 Lizardi-Cervera, J., Almeda, P., Guevara, L., et al. Hepatic encephalopathy: a review. Ann Hepatol 2 (2003), 122–130.
4. 4 Olde Damink, S.W., Dejong, C.H., Jalan, R., Review article: hyperammonaemic and catabolic consequences of upper gastrointestinal bleeding in cirrhosis. Aliment Pharmacol Ther 29 (2009), 801–810.
5. 5 Strauss, E., da Costa, M.F., The importance of bacterial infections as precipitating factors of chronic hepatic encephalopathy in cirrhosis. Hepatogastroenterology 45 (1998), 900–904.
6. 6 Blei, A.T., Cordoba, J., Practice Parameters Committee of the American College of Gastroenterology. Hepatic encephalopathy. Am J Gastroenterol 96 (2001), 1968–1976.
7. 7 Bianchi, G.P., Marchesini, G., Fabbri, A., et al. Vegetable versus animal protein diet in cirrhotic patients with chronic encephalopathy. A randomized cross-over comparison. J Intern Med 233 (1993), 385–392.
8. 8 Mamiya, Y., Kanazawa, H., Kimura, Y., et al. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. Hepatol Res 30 (2004), 162–168.
9. 9 Guevara, M., Baccaro, M.E., Torre, A., et al. Hyponatremia is a risk factor of hepatic encephalopathy in patients with cirrhosis: a prospective study with time-dependent analysis. Am J Gastroenterol 104 (2009), 1382–1389.
10. 10 Assy, N., Rosser, B.G., Grahame, G.R., et al. Risk of sedation for upper GI endoscopy exacerbating subclinical hepatic encephalopathy in patients with cirrhosis. Gastrointest Endosc 49 (1999), 690–694.
11. 11 Kao, D., Roach, B., Park, H., et al. Fecal microbiota transplantation in the management of hepatic encephalopathy. Hepatology 63 (2016), 339–340.
12. 12 Bajaj, J.S., The role of microbiota in hepatic encephalopathy. Gut Microbes 5 (2014), 397–403.
13. 13 Bajaj, J.S., Heuman, D.M., Hylemon, P.B., et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications. J Hepatol 60 (2014), 940–947.
14. 14 Butterworth, R.F., Hepatic encephalopathy: a central neuroinflammatory disorder?. Hepatology 53 (2011), 1372–1376.
15. 15 Gupta, A., Dhiman, R.K., Kumari, S., et al. Role of small intestinal bacterial overgrowth and delayed gastrointestinal transit time in cirrhotic patients with minimal hepatic encephalopathy. J Hepatol 53 (2010), 849–855.
16. 16 Prasad, S., Dhiman, R.K., Duseja, A., et al. Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology 45 (2007), 549–559.
17. 17 Bass, N.M., Mullen, K.D., Sanyal, A., et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 362 (2010), 1071–1081.
18. 18 Shaheen, N.J., Stuart, E., Schmitz, S.M., et al. Pantoprazole reduces the size of postbanding ulcers after variceal band ligation: a randomized, controlled trial. Hepatology 41 (2005), 588–594.
19. 19 Garcia-Tsao, G., Sanyal, A.J., Grace, N.D., et al. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology 46 (2007), 922–938.
20. 20 Batuwitage, B.T., Kingham, J.G., Morgan, N.E., et al. Inappropriate prescribing of proton pump inhibitors in primary care. Postgrad Med J 83 (2007), 66–68.
21. 21 Kalaitzakis, E., Bjornsson, E., Inadequate use of proton-pump inhibitors in patients with liver cirrhosis. Eur J Gastroenterol Hepatol 20 (2008), 512–518.
22. 22 Lodato, F., Azzaroli, F., Di Girolamo, M., et al. Proton pump inhibitors in cirrhosis: tradition or evidence based practice?. World J Gastroenterol 14 (2008), 2980–2985.
23. 23 Dultz, G., Piiper, A., Zeuzem, S., et al. Proton pump inhibitor treatment is associated with the severity of liver disease and increased mortality in patients with cirrhosis. Aliment Pharmacol Ther 41 (2015), 459–466.
24. 24 Corleto, V.D., Festa, S., Di Giulio, E., et al. Proton pump inhibitor therapy and potential long-term harm. Curr Opin Endocrinol Diabetes Obes 21 (2014), 3–8.
25. 25 Yoshida, N., Yoshikawa, T., Tanaka, Y., et al. A new mechanism for anti-inflammatory actions of proton pump inhibitors–inhibitory effects on neutrophil-endothelial cell interactions. Aliment Pharmacol Ther 14:Suppl 1 (2000), 74–81.
26. 26 Lewis, S.J., Franco, S., Young, G., et al. Altered bowel function and duodenal bacterial overgrowth in patients treated with omeprazole. Aliment Pharmacol Ther 10 (1996), 557–561.
27. 27 Freedberg, D.E., Toussaint, N.C., Chen, S.P., et al. Proton pump inhibitors alter specific taxa in the human gastrointestinal microbiome: a crossover trial. Gastroenterology 149 (2015), 883–885.e9.
28. 28 Bavishi, C., Dupont, H.L., Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection. Aliment Pharmacol Ther 34 (2011), 1269–1281.
29. 29 Bajaj, J.S., Zadvornova, Y., Heuman, D.M., et al. Association of proton pump inhibitor therapy with spontaneous bacterial peritonitis in cirrhotic patients with ascites. Am J Gastroenterol 104 (2009), 1130–1134.
30. 30 Wu, C.Y., Chen, Y.J., Ho, H.J., et al. Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection. JAMA 308 (2012), 1906–1914.
31. 31 Wu, C.Y., Chan, F.K., Wu, M.S., et al. Histamine2-receptor antagonists are an alternative to proton pump inhibitor in patients receiving clopidogrel. Gastroenterology 139 (2010), 1165–1171.
32. 32 Cheng, C.L., Kao, Y.H., Lin, S.J., et al. Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. Pharmacoepidemiol Drug Saf 20 (2011), 236–242.
33. 33 Charlson, M.E., Pompei, P., Ales, K.L., et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40 (1987), 373–383.
34. 34 Liu, C.Y., Chuang, Y.L., Chen, Y.J., et al. Incorporating development stratification of Taiwan townships into sampling design of large scale health interview survey. J Health Management (Chin) 4 (2006), 1–22.
35. 35 Yasuda, S., Horai, Y., Tomono, Y., et al. Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4'-hydroxylation status. Clin Pharmacol Ther 58 (1995), 143–154.
36. 36 VandenBranden, M., Ring, B.J., Binkley, S.N., et al. Interaction of human liver cytochromes P450 in vitro with LY307640, a gastric proton pump inhibitor. Pharmacogenetics 6 (1996), 81–91.
37. 37 Ishizaki, T., Horai, Y., Review article: cytochrome P450 and the metabolism of proton pump inhibitors–emphasis on rabeprazole. Aliment Pharmacol Ther 13:Suppl 3 (1999), 27–36.
38. 38 Choi, E.J., Lee, H.J., Kim, K.O., et al. Association between acid suppressive therapy and spontaneous bacterial peritonitis in cirrhotic patients with ascites. Scand J Gastroenterol 46 (2011), 616–620.
39. 39 Merli, M., Lucidi, C., Di Gregorio, V., et al. The chronic use of beta-blockers and proton pump inhibitors may affect the rate of bacterial infections in cirrhosis. Liver Int 35 (2015), 362–369.
40. 40 Lo, W.K., Chan, W.W., Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis. Clin Gastroenterol Hepatol 11 (2013), 483–490.
41. 41 Choung, R.S., Ruff, K.C., Malhotra, A., et al. Clinical predictors of small intestinal bacterial overgrowth by duodenal aspirate culture. Aliment Pharmacol Ther 33 (2011), 1059–1067.
42. 42 Imhann, F., Bonder, M.J., Vich Vila, A., et al. Proton pump inhibitors affect the gut microbiome. Gut 65 (2016), 740–748.
43. 43 Jackson, M.A., Goodrich, J.K., Maxan, M.E., et al. Proton pump inhibitors alter the composition of the gut microbiota. Gut 65 (2016), 749–756.
44. 44 Lunia, M.K., Sharma, B.C., Sharma, P., et al. Probiotics prevent hepatic encephalopathy in patients with cirrhosis: a randomized controlled trial. Clin Gastroenterol Hepatol 12 (2014), 1003–1008.e1.
45. 45 Ito, T., Jensen, R.T., Association of long-term proton pump inhibitor therapy with bone fractures and effects on absorption of calcium, vitamin B12, iron, and magnesium. Curr Gastroenterol Rep 12 (2010), 448–457.
46. 46 Lopes, P.J., Mei, M.F., Guardia, A.C., et al. Correlation between serum magnesium levels and hepatic encephalopathy in immediate post liver transplantation period. Transplant Proc 45 (2013), 1122–1125.
47. 47 Luk, C.P., Parsons, R., Lee, Y.P., et al. Proton pump inhibitor-associated hypomagnesemia: what do FDA data tell us?. Ann Pharmacother 47 (2013), 773–780.
48. 48 O'Leary, F., Allman-Farinelli, M., Samman, S., Vitamin B12 status, cognitive decline and dementia: a systematic review of prospective cohort studies. Br J Nutr 108 (2012), 1948–1961.
49. 49 Haenisch, B., von Holt, K., Wiese, B., et al. Risk of dementia in elderly patients with the use of proton pump inhibitors. Eur Arch Psychiatry Clin Neurosci 265 (2015), 419–428.
50. 50 Gomm, W., von Holt, K., Thome, F., et al. Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis. JAMA Neurol 73 (2016), 410–416.
51. 51 Mumtaz, K., Ahmed, U.S., Abid, S., et al. Precipitating factors and the outcome of hepatic encephalopathy in liver cirrhosis. J Coll Phys Surg Pak 20 (2010), 514–518.
52. 52 Strauss, E., Gomes de Sa Ribeiro Mde, F., Bacterial infections associated with hepatic encephalopathy: prevalence and outcome. Ann Hepatol 2 (2003), 41–45.
53. 53 Bajaj, J.S., Ratliff, S.M., Heuman, D.M., et al. Proton pump inhibitors are associated with a high rate of serious infections in veterans with decompensated cirrhosis. Aliment Pharmacol Ther 36 (2012), 866–874.
54. 54 Deshpande, A., Pant, C., Pasupuleti, V., et al. Association between proton pump inhibitor therapy and Clostridium difficile infection in a meta-analysis. Clin Gastroenterol Hepatol 10 (2012), 225–233.